A phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma

Cancer

Volumn 94, Issue 1, 2002, Pages 97-103

  Ryan, David P ^a,c   Kulke, Matthew H ^a   Fuchs, Charles S ^a   Grossbard, Michael L ^b   Grossman, Steven R ^a   Morgan, Jeffrey A ^a   Earle, Craig C ^a   Shivdasani, Ramesh ^a   Kim, Haesook ^a   Mayer, Robert J ^a   Clark, Jeffrey W ^a,c,d  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Chemotherapy; Docetaxel; Gemcitabine; Pancreatic neoplasms

Indexed keywords

DOCETAXEL; GEMCITABINE;

ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DYSPNEA; FATIGUE; FEMALE; FEVER; HUMAN; MALE; NEUTROPENIA; PANCREAS CARCINOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL; PANCREATIC NEOPLASMS; SURVIVAL ANALYSIS; TAXOIDS;

EID: 0036142182     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10202     Document Type: Article

References (29)

1. Cancer statistics, 2000
2. Pancreatic cancer: State-of-the-art care
3. Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas
4. Phase II study of gemcitabine in patients with advanced pancreatic cancer
5. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
6. Chemotherapy for advanced pancreatic cancer: It may no longer be ignored
7. Treatment of pancreatic cancer with docetaxel and granulocyte colony stimulating factor: A multicenter Phase II study
8. A Phase II study: Docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma
9. A Phase I study of gemcitabine and docetaxel in patients with metastatic solid tumors
10. Docetaxel and gemcitabine activity in NSCLC cell lines and in primary cultures from human lung cancer
11. Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies
12. Phase VII trial of sequential docetaxel and gemcitabine - A new schedule based on preclinical testing with the BOT-2 breast cancer cell line
13. Incidence of pulmonary and non-hematologic toxicities related to gemcitabine
14. A Phase I-II study of gemcitabine and docetaxel in advanced pancreatic cancer: A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)
15. A Phase II trial of biweekly high dose gemcitabine for patients with metastatic pancreatic adenocarcinoma
16. A Phase II study of gemcitabine and 5-fluorouracil in metastatic pancreatic cancer: An Eastern Cooperative Oncology Group study (E3296)
17. Phase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinoma
18. Phase II study of docetaxel in patients with metastatic pancreatic cancer: A Japanese cooperative study
19. A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)
20. Phase II trial of paclitaxel and granulocyte colony-stimulating factor in patients with pancreatic carcinoma: A Southwest Oncology Group study
21. Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer
22. Phase II study of gemcitabine and cisplatin in advanced or metastatic pancreatic cancer
23. Gemcitabine and cisplatin in the treatment of advanced and metastatic pancreatic cancer
24. Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: A Phase II study of the Greek Cooperative Group for Pancreatic Cancer
25. Randomized Phase II trial of dose intense gemcitabine by standard infusion vs. fixed dose rate in metastatic pancreatic carcinoma
26. Treatment of pancreatic cancer with docetaxel and granulocyte colony-stimulating factor: A multicenter Phase II study
27. Phase II study of gemcitabine and docetaxel in patients with metastic pancreatic cancer
28. Optimal two-stage designs for phase II clinical trails
29. Nonparametric estimation from incomplete observation